UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of  August 2016
Commission File Number 000- 50112
RepliCel Life Sciences Inc.
(Translation of registrant’s name into English)
Suite 2020 – 401 West Georgia Street, Vancouver, British Columbia  V6B 5A1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.     Form 20-F  [X]  Form 40-F  [  ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  [  ]
Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
 


SUBMITTED HEREWITH

99.1           RepliCel Life Sciences Announces Completion of the Final Injection in its Tendon Repair Clinical Trial
 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RepliCel Life Sciences Inc.
/s/ Lee Buckler                                                
Lee Buckler, President & CEO
Date:  August 11, 2016


RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more RepliCel Life Sciences (PK) Charts.
RepliCel Life Sciences (PK) (USOTC:REPCF)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more RepliCel Life Sciences (PK) Charts.